Case Analysis on Real Life Incidence of Photodynamic Therapy (PDT) Safety Outcomes (CALIPSO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01203163
Recruitment Status : Withdrawn (Sponsor cancelled the study)
First Posted : September 16, 2010
Last Update Posted : May 9, 2012
Information provided by (Responsible Party):
Pinnacle Biologics Inc.

Brief Summary:

Three main adverse reactions, namely photosensitivity (reaction that is similar to sunburn), oesophageal stenosis (narrowing or closure of the food pipe), perforation of the treated area (a tear or puncture of the tissue), have been identified in research studies evaluating photodynamic therapy (PDT) with porfimer sodium. Because of the low incidence of the disease or the variation in the occurrence of these adverse reactions among different indications, it is difficult to determine the occurrence and frequency of these safety issues in routine clinical practice.

This post-marketing safety surveillance registry is set-up to evaluate the safety of PDT using porfimer sodium. A registry allows the collection of data to evaluate real-world results in the practice of medicine. The registry will monitor the patient's health and any events, with a main focus on photosensitivity, oesophageal stenosis, and perforation of the treated area. This registry will involve 500 patients, across 20 to 36 hospitals in the US and Europe, scheduled to receive an injection of porfimer sodium with PDT for the treatment of lung cancer, esophageal [food pipe] cancer, or high-grade dysplasia (HGD) (precancerous change in the food pipe tissue) in Barrett's esophagus.

Condition or disease
Esophageal Cancer Lung Cancer Barrett's Esophagus

Detailed Description:
Patients will be enrolled in the registry upon injection of the porfimer sodium. During normal medical examination, criteria for entry onto the registry will be verified to confirm eligibility, and medical procedures including demographic information, disease history, medical history, physical exam, and clinical laboratory testing performed under normal practice will be collected. Patients will receive PDT as per current practice and will be repeated as per the physician's judgment. All patients will be assessed as per current practice, that is usually at least three times, after a PDT session. Additional visits will be sought for those patients who are presenting photosensitivity reaction, esophageal stenosis, perforation at the site of laser light application, or any unresolved serious adverse reactions at the third visit after treatment. All patients will be requested by their physician to complete a two-part Daily Diary to record adverse reactions using a check-list form and a general section for reporting any adverse events and intake of concomitant medications at the time of the adverse event.

Study Type : Observational
Actual Enrollment : 0 participants
Time Perspective: Prospective
Official Title: Case Analysis on Real Life Incidence of PDT Safety Outcomes: Multicentre, Observational Post-marketing Safety Surveillance Registry of Patients Exposed to Photodynamic Therapy With Porfimer Sodium: The CALIPSO Registry

Resource links provided by the National Library of Medicine

U.S. FDA Resources

PDT with porfimer sodium

Primary Outcome Measures :
  1. Proportion of patients experiencing Adverse Reactions of Special Interest [ Time Frame: 3 months ]
    Proportion of patients experiencing photosensitivity reaction, oesophageal stenosis, and/or perforation at the site of laser light application after PDT.

Secondary Outcome Measures :
  1. Incidence of the photosensitivity reaction in patients with liver insufficiency (disease) [ Time Frame: 3 months ]
    Possible differences in the incidence of the photosensitivity reaction between patients with and without liver insufficiency

  2. Relationships between photosensitivity reaction and skin color [ Time Frame: 3 months ]
  3. Overall safety in patients with renal insufficiency (disease) [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients suffering from esophageal cancer, lung cancer, or HGD in Barrett's esophagus and scheduled to undergo PDT with porfimer sodium

Inclusion Criteria:

  • Patients scheduled to undergo PDT with Photofrin
  • Patients must have the mental, literate, and legal ability to give a written informed consent, which must comply with the International Conference on Harmonization (ICH) guidelines and local requirements.

Exclusion Criteria:

  • Patients treated with Photosan®
  • Patients being treated with any investigational drug or participating in any interventional studies, with the exception of investigational photoprotection measures.
  • Patients who are unable or unwilling to complete the follow-up evaluations required for the registry.

Responsible Party: Pinnacle Biologics Inc. Identifier: NCT01203163     History of Changes
Other Study ID Numbers: MA-PO-PHORC07-01
First Posted: September 16, 2010    Key Record Dates
Last Update Posted: May 9, 2012
Last Verified: May 2012

Keywords provided by Pinnacle Biologics Inc.:
porfimer sodium
esophageal cancer

Additional relevant MeSH terms:
Esophageal Neoplasms
Barrett Esophagus
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Abnormalities
Dihematoporphyrin Ether
Antineoplastic Agents
Dermatologic Agents
Photosensitizing Agents